Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Cell Genesys, Inc. (CEGE) Combats Prostate Cancer; Publishes Results

According to the American Cancer Society, roughly 218,890 new cases of prostate cancer were diagnosed in the United States in 2007; one in six men will be diagnosed with prostate cancer during his lifetime, though one in 34 will die from it. Still, the latter statistic is little comfort to those afflicted with the disease. Cell Genesys, Inc. (NASDAQ: CEGE) is engaged in fighting the cancer, conducting clinical trials of GVAX immunotherapy for prostate cancer.

According to Cell Genesys’ trials completed in 2007, the GVAX cell-based immunotherapy generated antibody responds to an array of antigens known to be associated with prostate cancer, and induced the activity of antigens not previously known to be linked to the cancer.

Peter K. Working, Ph.D., senior vice president of Research and Development at Cell Geneys told Medical News Today the results of each test differed with each patient, insinuating that GVAX has the ability to create immune response from a broad range of tumor-associated antigens.

“That the majority of antibody responses are unique to individual patients is further evidence that the non patient-specific format of GVAX immunotherapies is capable of inducing unique, patient-specific immune responses,” stated Working. “Moreover, the fact that many of these antigens have not before been associated with prostate cancer, further suggests that a multivalent antigen immunotherapy like GVAX immunotherapy may provide the best potential for inducing an effective anti-tumor immune response, especially for heterogeneous cancers such as prostate cancer.”

The company’s medical findings and advancements were published in a Medical News Today article, more information can be found at http://www.cellgenesys.com.

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *